NASDAQ:AKAO - Achaogen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.42 -0.03 (-0.24 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$12.42
Today's Range$12.00 - $12.67
52-Week Range$9.83 - $25.22
Volume1.50 million shs
Average Volume730,165 shs
Market Capitalization$557.71 million
P/E Ratio-3.92
Dividend YieldN/A
Beta0.96
Achaogen logoAchaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKAO
CUSIPN/A
Phone650-800-3636

Debt

Debt-to-Equity Ratio0.24
Current Ratio7.01
Quick Ratio7.01

Price-To-Earnings

Trailing P/E Ratio-3.92
Forward P/E Ratio-3.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.18 million
Price / Sales49.77
Cash FlowN/A
Price / CashN/A
Book Value$2.88 per share
Price / Book4.31

Profitability

EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-2,384.08%
Return on Equity-97.86%
Return on Assets-62.39%

Miscellaneous

Employees230
Outstanding Shares44,800,000

The Truth About Cryptocurrencies

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) released its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.17. The biopharmaceutical company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $1.25 million. Achaogen had a negative return on equity of 97.86% and a negative net margin of 2,384.08%. View Achaogen's Earnings History.

What price target have analysts set for AKAO?

9 brokerages have issued 1-year price targets for Achaogen's stock. Their forecasts range from $16.00 to $29.00. On average, they anticipate Achaogen's share price to reach $22.1250 in the next year. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:
  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (5/9/2018)
  • 2. Mizuho analysts commented, "We are reducing our PT from $28 to $20 based on a worst-case scenario analysis assuming no revenues from BSI or any other potential usages and an additional capital raise of $200 million in 2019 (an amount we see as adequate to carry the company to break-even point). We would be buyers on weakness as we believe Achaogen has an approvable drug in cUTI and there could be upside potential from Plazomicin in Carbapenem- resistant enterobacteriaceae (CRE) cases over time." (5/3/2018)
  • 3. Needham & Company LLC analysts commented, "Plazomicin will be discussed at an FDA Advisory Committee (AdCom) mtg 5/2/18. Achaogen completed two Phase 3 trials, a standard cUTI trial (EPIC) and the other a descriptive trial in patients with HABP/VABP or bloodstream infections caused by Carbapenem Resistant Enterobacteriaceae (CRE; CARE). Both trials had positive outcomes, w/ the latter surprisingly demonstrating superiority to comparator colistin. Achaogen is seeking a label in both cUTI and Bloodstream infections, although Bloodstream is controversial given the descriptive nature of the CARE trial. The Avycaz and Cresemba AdCom mtgs are most relevant to analysis of the plazomicin mtg and we have a modest bias towards a vote in favor of including both indications on plazomicin label. Our note details recent antibiotic FDA reviews and individual voting histories. BUY." (4/30/2018)
  • 4. HC Wainwright analysts commented, "We find no big surprises in the FDA analyses. This morning, FDA released its Briefing Document for the May 2, 2018 meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) to review the NDA for Achaogen’s plazomicin for the proposed indications for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis (AP); and bloodstream infections (BSI), in adults." (4/30/2018)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:
  • Mr. Blake Wise, CEO & Director (Age 47)
  • Dr. Kenneth J. Hillan, Pres, Director and Pres of R&D (Age 57)
  • Mr. Tobin C. Schilke, Chief Financial Officer (Age 43)
  • Dr. Lee Swem, Chief Scientific Officer (Age 42)
  • Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)

Has Achaogen been receiving favorable news coverage?

Media coverage about AKAO stock has trended somewhat negative recently, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Achaogen earned a media sentiment score of -0.04 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 48.87 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Achaogen's major shareholders?

Achaogen's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.47%), Prosight Management LP (1.48%), UBS Group AG (0.66%), Candriam Luxembourg S.C.A. (0.50%), Gabelli Funds LLC (0.39%) and Fiera Capital Corp (0.37%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Which major investors are selling Achaogen stock?

AKAO stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Kenneth J Hillan and Tobin Schilke. View Insider Buying and Selling for Achaogen.

Which major investors are buying Achaogen stock?

AKAO stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, RMB Capital Management LLC, Gabelli Funds LLC, Prosight Management LP, Gamco Investors INC. ET AL, BlackRock Inc., Engineers Gate Manager LP and Candriam Luxembourg S.C.A.. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen.

How do I buy shares of Achaogen?

Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of AKAO stock can currently be purchased for approximately $12.42.

How big of a company is Achaogen?

Achaogen has a market capitalization of $557.71 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]


MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  463
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.